Fig 2: In vivo biodistribution experiments in nude mice bearing MIA PaCa-2 and A4 xenografts of radiolabeled anti-CD147 antibody 059-053.Samples were collected and weighted, and radioactivity was measured at day 1 (white bars), 2 (dot bars), 4 (gray bars) and 6 (black bars) after intravenous injection of 37 kBq each of [89Zr]059-053 (A) and [125I]059-053 (B). Data are expressed as mean ± SD (n = 5). *P<0.01 vs. [89Zr]059-053 tumor uptake at each time point analyzed by ANOVA with the Student–Newman–Keuls method multiple comparison test.

Fig 3: Individual tumor growth curves of BxPC-3 tumors in mice treated with single and combination regimens. The mice were injected with gemcitabine (gem, 240 mg/kg body weight) alone, 3.7 MBq of 90Y-labeled anti-CD147 antibody 059-053 (RIT) alone, and the combination of gem plus RIT (one and two cycles) shown in the (A). Tumor size was measured at least twice a week. Survival curves were plotted based on the endpoint of 150% tumor volume (B).

Fig 4: Individual body weight curves of mice bearing BxPC-3 tumors injected with 90Y-labeled anti-CD147 antibody 059-053. The injected doses were 0 (intact antibody only), 0.925 MBq, 1.85 MBq and 3.7 MBq of 90Y-059-053. Body weight was measured at least twice a week.

Fig 5: Immunostaining reveals cellular localization of SARS-CoV-2 receptors and processing enzymes in COPD and donor lung tissue. High-magnification images showing ACE2, TMPRSS2, Furin, Ezrin, and CD147 immunostaining in bronchial, parenchymal, and vascular compartments on corresponding serial sections of donor and COPD tissue. Scalebar = 20 µm. Black arrowhead, bronchial epithelium; black arrow, alveolar epithelial type II cells; white arrowhead, vascular endothelium; gray arrowhead, erythrocytes; asterisks, inflammatory cells.